Successful Desensitization to Oral Dasatinib in Immediate Hypersensitivity Reaction
A case report is presented, discussing the successful desensitization to dasatinib in a patient with chronic myeloid leukemia (CML) who experienced an immediate hypersensitivity reaction to the drug. The patient had previously been treated with imatinib but developed imatinib-induced pseudoporphyria...
Gespeichert in:
| Veröffentlicht in: | Journal of investigational allergology & clinical immunology 2024-07, Vol.34 (4), p.274-276 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 276 |
|---|---|
| container_issue | 4 |
| container_start_page | 274 |
| container_title | Journal of investigational allergology & clinical immunology |
| container_volume | 34 |
| creator | Ruano-Zaragoza, M Torrent-Rodríguez, A Araujo-Sanchez, G Ribó, P Loli-Ausejo, D Solis, K Sánchez-Fernández, M C Bolaños, J Bolós, U López, C Ruiz, S Pascal, M Bartra, J Muñoz-Cano, R |
| description | A case report is presented, discussing the successful desensitization to dasatinib in a patient with chronic myeloid leukemia (CML) who experienced an immediate hypersensitivity reaction to the drug. The patient had previously been treated with imatinib but developed imatinib-induced pseudoporphyria, leading to discontinuation of treatment. The patient then started dasatinib but experienced a non-pruritic maculopapular exanthema and severe headache after the second dose. The patient was referred to the allergy unit, where a skin prick test and basophil activation test were performed. The skin prick test with dasatinib was negative, but the basophil activation test was positive. Considering the need to continue CML treatment and the patient's intolerance to other tyrosine kinase inhibitors (TKIs), a rapid dasatinib desensitization protocol was initiated, which was successful. The patient continues to tolerate dasatinib and the basophil activation test result has become negative. This case highlights the importance of desensitization in managing hypersensitivity reactions to TKIs and the potential for successful desensitization to dasatinib in patients with immediate hypersensitivity reactions. |
| doi_str_mv | 10.18176/jiaci.0985 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2905524456</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3125543022</sourcerecordid><originalsourceid>FETCH-LOGICAL-c242t-bae51971ff3d220b1c6135d3ea279ec3bf3e1f9368a85a794b8f6ec5bd6b38333</originalsourceid><addsrcrecordid>eNpdkEtLAzEURoMotlZX7mXAjSBT85hkMkupjxYKBavrIcncQEpnpiYzQv31pg9duLqXy_k-Lgeha4LHRJJcPKycMm6MC8lP0JCIQqZYYnkad0xkWmAhB-gihBXGLBcyP0cDJgkjlJIhWi57YyAE26-TJwjQBNe5b9W5tkm6Nll4Fe8qxEPjdOKaZFbXUDnVQTLdbsAfE1-u2yZvoMwueInOrFoHuDrOEfp4eX6fTNP54nU2eZynhma0S7UCToqcWMsqSrEmRhDGKwaK5gUYpi0DYgsmpJJc5UWmpRVguK6EZpIxNkJ3h96Nbz97CF1Zu2BgvVYNtH0oaYE5p1nGRURv_6GrtvdN_K6MIjjPGKY0UvcHyvg2BA-23HhXK78tCS73rsu963LnOtI3x85eRyd_7K9c9gMieHrv</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3125543022</pqid></control><display><type>article</type><title>Successful Desensitization to Oral Dasatinib in Immediate Hypersensitivity Reaction</title><source>MEDLINE</source><source>EZB Electronic Journals Library</source><creator>Ruano-Zaragoza, M ; Torrent-Rodríguez, A ; Araujo-Sanchez, G ; Ribó, P ; Loli-Ausejo, D ; Solis, K ; Sánchez-Fernández, M C ; Bolaños, J ; Bolós, U ; López, C ; Ruiz, S ; Pascal, M ; Bartra, J ; Muñoz-Cano, R</creator><creatorcontrib>Ruano-Zaragoza, M ; Torrent-Rodríguez, A ; Araujo-Sanchez, G ; Ribó, P ; Loli-Ausejo, D ; Solis, K ; Sánchez-Fernández, M C ; Bolaños, J ; Bolós, U ; López, C ; Ruiz, S ; Pascal, M ; Bartra, J ; Muñoz-Cano, R</creatorcontrib><description>A case report is presented, discussing the successful desensitization to dasatinib in a patient with chronic myeloid leukemia (CML) who experienced an immediate hypersensitivity reaction to the drug. The patient had previously been treated with imatinib but developed imatinib-induced pseudoporphyria, leading to discontinuation of treatment. The patient then started dasatinib but experienced a non-pruritic maculopapular exanthema and severe headache after the second dose. The patient was referred to the allergy unit, where a skin prick test and basophil activation test were performed. The skin prick test with dasatinib was negative, but the basophil activation test was positive. Considering the need to continue CML treatment and the patient's intolerance to other tyrosine kinase inhibitors (TKIs), a rapid dasatinib desensitization protocol was initiated, which was successful. The patient continues to tolerate dasatinib and the basophil activation test result has become negative. This case highlights the importance of desensitization in managing hypersensitivity reactions to TKIs and the potential for successful desensitization to dasatinib in patients with immediate hypersensitivity reactions.</description><identifier>ISSN: 1018-9068</identifier><identifier>EISSN: 1698-0808</identifier><identifier>DOI: 10.18176/jiaci.0985</identifier><identifier>PMID: 38131221</identifier><language>eng</language><publisher>Spain: Esmon Publicidad</publisher><subject>Administration, Oral ; Antineoplastic Agents - administration & dosage ; Antineoplastic Agents - adverse effects ; Chronic myeloid leukemia ; Dasatinib - administration & dosage ; Dasatinib - adverse effects ; Desensitization, Immunologic - methods ; Drug Hypersensitivity - diagnosis ; Drug Hypersensitivity - etiology ; Drug Hypersensitivity - immunology ; Drug Hypersensitivity - therapy ; Exanthema ; Female ; Humans ; Hypersensitivity (immediate) ; Hypersensitivity, Immediate - etiology ; Hypersensitivity, Immediate - immunology ; Imatinib ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy ; Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology ; Leukocytes (basophilic) ; Male ; Middle Aged ; Myeloid leukemia ; Protein Kinase Inhibitors - administration & dosage ; Protein Kinase Inhibitors - adverse effects ; Skin tests ; Tyrosine kinase inhibitors</subject><ispartof>Journal of investigational allergology & clinical immunology, 2024-07, Vol.34 (4), p.274-276</ispartof><rights>Copyright Esmon Publicidad 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38131221$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ruano-Zaragoza, M</creatorcontrib><creatorcontrib>Torrent-Rodríguez, A</creatorcontrib><creatorcontrib>Araujo-Sanchez, G</creatorcontrib><creatorcontrib>Ribó, P</creatorcontrib><creatorcontrib>Loli-Ausejo, D</creatorcontrib><creatorcontrib>Solis, K</creatorcontrib><creatorcontrib>Sánchez-Fernández, M C</creatorcontrib><creatorcontrib>Bolaños, J</creatorcontrib><creatorcontrib>Bolós, U</creatorcontrib><creatorcontrib>López, C</creatorcontrib><creatorcontrib>Ruiz, S</creatorcontrib><creatorcontrib>Pascal, M</creatorcontrib><creatorcontrib>Bartra, J</creatorcontrib><creatorcontrib>Muñoz-Cano, R</creatorcontrib><title>Successful Desensitization to Oral Dasatinib in Immediate Hypersensitivity Reaction</title><title>Journal of investigational allergology & clinical immunology</title><addtitle>J Investig Allergol Clin Immunol</addtitle><description>A case report is presented, discussing the successful desensitization to dasatinib in a patient with chronic myeloid leukemia (CML) who experienced an immediate hypersensitivity reaction to the drug. The patient had previously been treated with imatinib but developed imatinib-induced pseudoporphyria, leading to discontinuation of treatment. The patient then started dasatinib but experienced a non-pruritic maculopapular exanthema and severe headache after the second dose. The patient was referred to the allergy unit, where a skin prick test and basophil activation test were performed. The skin prick test with dasatinib was negative, but the basophil activation test was positive. Considering the need to continue CML treatment and the patient's intolerance to other tyrosine kinase inhibitors (TKIs), a rapid dasatinib desensitization protocol was initiated, which was successful. The patient continues to tolerate dasatinib and the basophil activation test result has become negative. This case highlights the importance of desensitization in managing hypersensitivity reactions to TKIs and the potential for successful desensitization to dasatinib in patients with immediate hypersensitivity reactions.</description><subject>Administration, Oral</subject><subject>Antineoplastic Agents - administration & dosage</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Chronic myeloid leukemia</subject><subject>Dasatinib - administration & dosage</subject><subject>Dasatinib - adverse effects</subject><subject>Desensitization, Immunologic - methods</subject><subject>Drug Hypersensitivity - diagnosis</subject><subject>Drug Hypersensitivity - etiology</subject><subject>Drug Hypersensitivity - immunology</subject><subject>Drug Hypersensitivity - therapy</subject><subject>Exanthema</subject><subject>Female</subject><subject>Humans</subject><subject>Hypersensitivity (immediate)</subject><subject>Hypersensitivity, Immediate - etiology</subject><subject>Hypersensitivity, Immediate - immunology</subject><subject>Imatinib</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</subject><subject>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology</subject><subject>Leukocytes (basophilic)</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Myeloid leukemia</subject><subject>Protein Kinase Inhibitors - administration & dosage</subject><subject>Protein Kinase Inhibitors - adverse effects</subject><subject>Skin tests</subject><subject>Tyrosine kinase inhibitors</subject><issn>1018-9068</issn><issn>1698-0808</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkEtLAzEURoMotlZX7mXAjSBT85hkMkupjxYKBavrIcncQEpnpiYzQv31pg9duLqXy_k-Lgeha4LHRJJcPKycMm6MC8lP0JCIQqZYYnkad0xkWmAhB-gihBXGLBcyP0cDJgkjlJIhWi57YyAE26-TJwjQBNe5b9W5tkm6Nll4Fe8qxEPjdOKaZFbXUDnVQTLdbsAfE1-u2yZvoMwueInOrFoHuDrOEfp4eX6fTNP54nU2eZynhma0S7UCToqcWMsqSrEmRhDGKwaK5gUYpi0DYgsmpJJc5UWmpRVguK6EZpIxNkJ3h96Nbz97CF1Zu2BgvVYNtH0oaYE5p1nGRURv_6GrtvdN_K6MIjjPGKY0UvcHyvg2BA-23HhXK78tCS73rsu963LnOtI3x85eRyd_7K9c9gMieHrv</recordid><startdate>20240729</startdate><enddate>20240729</enddate><creator>Ruano-Zaragoza, M</creator><creator>Torrent-Rodríguez, A</creator><creator>Araujo-Sanchez, G</creator><creator>Ribó, P</creator><creator>Loli-Ausejo, D</creator><creator>Solis, K</creator><creator>Sánchez-Fernández, M C</creator><creator>Bolaños, J</creator><creator>Bolós, U</creator><creator>López, C</creator><creator>Ruiz, S</creator><creator>Pascal, M</creator><creator>Bartra, J</creator><creator>Muñoz-Cano, R</creator><general>Esmon Publicidad</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>20240729</creationdate><title>Successful Desensitization to Oral Dasatinib in Immediate Hypersensitivity Reaction</title><author>Ruano-Zaragoza, M ; Torrent-Rodríguez, A ; Araujo-Sanchez, G ; Ribó, P ; Loli-Ausejo, D ; Solis, K ; Sánchez-Fernández, M C ; Bolaños, J ; Bolós, U ; López, C ; Ruiz, S ; Pascal, M ; Bartra, J ; Muñoz-Cano, R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c242t-bae51971ff3d220b1c6135d3ea279ec3bf3e1f9368a85a794b8f6ec5bd6b38333</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Administration, Oral</topic><topic>Antineoplastic Agents - administration & dosage</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Chronic myeloid leukemia</topic><topic>Dasatinib - administration & dosage</topic><topic>Dasatinib - adverse effects</topic><topic>Desensitization, Immunologic - methods</topic><topic>Drug Hypersensitivity - diagnosis</topic><topic>Drug Hypersensitivity - etiology</topic><topic>Drug Hypersensitivity - immunology</topic><topic>Drug Hypersensitivity - therapy</topic><topic>Exanthema</topic><topic>Female</topic><topic>Humans</topic><topic>Hypersensitivity (immediate)</topic><topic>Hypersensitivity, Immediate - etiology</topic><topic>Hypersensitivity, Immediate - immunology</topic><topic>Imatinib</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy</topic><topic>Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology</topic><topic>Leukocytes (basophilic)</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Myeloid leukemia</topic><topic>Protein Kinase Inhibitors - administration & dosage</topic><topic>Protein Kinase Inhibitors - adverse effects</topic><topic>Skin tests</topic><topic>Tyrosine kinase inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ruano-Zaragoza, M</creatorcontrib><creatorcontrib>Torrent-Rodríguez, A</creatorcontrib><creatorcontrib>Araujo-Sanchez, G</creatorcontrib><creatorcontrib>Ribó, P</creatorcontrib><creatorcontrib>Loli-Ausejo, D</creatorcontrib><creatorcontrib>Solis, K</creatorcontrib><creatorcontrib>Sánchez-Fernández, M C</creatorcontrib><creatorcontrib>Bolaños, J</creatorcontrib><creatorcontrib>Bolós, U</creatorcontrib><creatorcontrib>López, C</creatorcontrib><creatorcontrib>Ruiz, S</creatorcontrib><creatorcontrib>Pascal, M</creatorcontrib><creatorcontrib>Bartra, J</creatorcontrib><creatorcontrib>Muñoz-Cano, R</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of investigational allergology & clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ruano-Zaragoza, M</au><au>Torrent-Rodríguez, A</au><au>Araujo-Sanchez, G</au><au>Ribó, P</au><au>Loli-Ausejo, D</au><au>Solis, K</au><au>Sánchez-Fernández, M C</au><au>Bolaños, J</au><au>Bolós, U</au><au>López, C</au><au>Ruiz, S</au><au>Pascal, M</au><au>Bartra, J</au><au>Muñoz-Cano, R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Successful Desensitization to Oral Dasatinib in Immediate Hypersensitivity Reaction</atitle><jtitle>Journal of investigational allergology & clinical immunology</jtitle><addtitle>J Investig Allergol Clin Immunol</addtitle><date>2024-07-29</date><risdate>2024</risdate><volume>34</volume><issue>4</issue><spage>274</spage><epage>276</epage><pages>274-276</pages><issn>1018-9068</issn><eissn>1698-0808</eissn><abstract>A case report is presented, discussing the successful desensitization to dasatinib in a patient with chronic myeloid leukemia (CML) who experienced an immediate hypersensitivity reaction to the drug. The patient had previously been treated with imatinib but developed imatinib-induced pseudoporphyria, leading to discontinuation of treatment. The patient then started dasatinib but experienced a non-pruritic maculopapular exanthema and severe headache after the second dose. The patient was referred to the allergy unit, where a skin prick test and basophil activation test were performed. The skin prick test with dasatinib was negative, but the basophil activation test was positive. Considering the need to continue CML treatment and the patient's intolerance to other tyrosine kinase inhibitors (TKIs), a rapid dasatinib desensitization protocol was initiated, which was successful. The patient continues to tolerate dasatinib and the basophil activation test result has become negative. This case highlights the importance of desensitization in managing hypersensitivity reactions to TKIs and the potential for successful desensitization to dasatinib in patients with immediate hypersensitivity reactions.</abstract><cop>Spain</cop><pub>Esmon Publicidad</pub><pmid>38131221</pmid><doi>10.18176/jiaci.0985</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1018-9068 |
| ispartof | Journal of investigational allergology & clinical immunology, 2024-07, Vol.34 (4), p.274-276 |
| issn | 1018-9068 1698-0808 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2905524456 |
| source | MEDLINE; EZB Electronic Journals Library |
| subjects | Administration, Oral Antineoplastic Agents - administration & dosage Antineoplastic Agents - adverse effects Chronic myeloid leukemia Dasatinib - administration & dosage Dasatinib - adverse effects Desensitization, Immunologic - methods Drug Hypersensitivity - diagnosis Drug Hypersensitivity - etiology Drug Hypersensitivity - immunology Drug Hypersensitivity - therapy Exanthema Female Humans Hypersensitivity (immediate) Hypersensitivity, Immediate - etiology Hypersensitivity, Immediate - immunology Imatinib Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology Leukocytes (basophilic) Male Middle Aged Myeloid leukemia Protein Kinase Inhibitors - administration & dosage Protein Kinase Inhibitors - adverse effects Skin tests Tyrosine kinase inhibitors |
| title | Successful Desensitization to Oral Dasatinib in Immediate Hypersensitivity Reaction |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T10%3A57%3A38IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Successful%20Desensitization%20to%20Oral%20Dasatinib%20in%20Immediate%20Hypersensitivity%20Reaction&rft.jtitle=Journal%20of%20investigational%20allergology%20&%20clinical%20immunology&rft.au=Ruano-Zaragoza,%20M&rft.date=2024-07-29&rft.volume=34&rft.issue=4&rft.spage=274&rft.epage=276&rft.pages=274-276&rft.issn=1018-9068&rft.eissn=1698-0808&rft_id=info:doi/10.18176/jiaci.0985&rft_dat=%3Cproquest_cross%3E3125543022%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3125543022&rft_id=info:pmid/38131221&rfr_iscdi=true |